The drop below 5% removes the group from future 13G filing obligations, reducing transparency into their ongoing trading. Monitor for further insider selling or a potential conversion to a 13D if the group re-engages actively. The Q3 earnings (Nov 5) showed strong revenue growth but continued net losses, which may have prompted the reduction.
Price Chart
How similar events traded
Executive Summary
Rubicon Funds and Adam Boehler filed an amended Schedule 13G disclosing that they have ceased to be beneficial owners of more than 5% of Evolent Health's Class A common stock. The group's aggregate stake dropped to 4.99%, representing 5,641,123 shares, down from a prior above-5% position. This signals a material reduction in insider/passive holder exposure.
Key Financial Metrics
Key Facts
- Rubicon Fund II LP, Rubicon Fund II PF LP, Rubicon OP GP II LP, Rubicon OP GP II LLC, Rubicon Founders LLC and Adam Boehler filed SC 13G/A on Nov 13, 2026
- The group's aggregate beneficial ownership fell to 4.99% (5,641,123 shares), below the 5% threshold
- Rubicon Fund II LP held 4,947,404 shares (4.38%) and Rubicon Fund II PF LP held 693,719 shares (0.61%)
- The filing states each reporting person 'has ceased to be the beneficial owner of more than five percent of the class of securities'
- Prior SC 13G/A filings from Morgan Stanley (Sep 2026) and Vanguard (Mar 2026) show other passive holders were also adjusting positions
Financial Impact
Group reduced stake from above 5% to 4.99%, representing 5,641,123 shares worth approximately $28.2M at the $5.00/share snapshot price (market cap $566M)
Risk Factors
- Loss of a significant passive holder could signal reduced confidence in the stock's near-term prospects
- The group may continue to sell without further public disclosure since they are now below 5%
- Other large holders (BlackRock, Vanguard, Marshall Wace) may adjust positions in response
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000950103-26-017513 |
| Document: 0000950103-26-017513-index-headers.html | 0000950103-26-017513 |
| Document: 0000950103-26-017513-index.html | 0000950103-26-017513 |
| Document: 0000950103-26-017513.txt | 0000950103-26-017513 |
Track record
8 reports on EVH
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $4.82 Now $4.83 −0.31% settles Dec 15
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Viewing Entry $4.74 Now $4.83 −1.90% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $4.54 Now $4.83 +6.39% settles Dec 4
- Aug 6, 202614w ago 8-K Mixed 6/10 Entry $3.59 to $4.26 Now $4.83 +34.54% ▲ +18.66% +18.06% vs SPY
- Jul 8, 202618w ago Press Release Neutral 1/10 Entry $5.63 to $3.59 Now $4.83 −14.21% ▼ −36.23% −38.48% vs SPY
- Apr 24, 202629w ago DEFA14A Neutral 2/10 Entry $3.47 to $3.83 Now $4.83 +39.19% ▲ +10.37% +5.42% vs SPY
- Feb 24, 202637w ago 8-K Mixed 6/10 Entry $3.14 to $2.27 Now $4.83 +53.82% ▼ −27.71% −22.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers